The American Academy of Pediatrics places emphasis on increasing breastfeeding in the United States. A common reason for the cessation of breastfeeding is the use of medication by the nursing mother and advice by her physician to stop nursing. Such advice may not be warranted. This statement is intended to supply the pediatrician, obstetrician, and family physician with data, if known, concerning the excretion of drugs into human milk. Most drugs likely to be prescribed to the nursing mother should have no effect on milk supply or on infant well-being. This information is important not only to protect nursing infants from untoward effects of maternal medication but also to allow effective pharmacologic treatment of breastfeeding mothers. Nicotine, psychotropic drugs, and silicone implants are 3 important topics reviewed in this statement.
INTRODUCTION
A statement on the transfer of drugs and chemicals into human milk was first published in 1983, 1 with revisions in 1989 2 and 1994. 3 Information continues to become available. The current statement is intended to revise the lists of agents transferred into human milk and describe their possible effects on the infant or on lactation, if known (Tables 1-7 ). If a pharmacologic or chemical agent does not appear in the tables, it does not mean that it is not transferred into human milk or that it does not have an effect on the infant; it only indicates that there were no reports found in the literature. These tables should assist the physician in counseling a nursing mother regarding breastfeeding when the mother has a condition for which a drug is medically indicated.
BREASTFEEDING AND SMOKING
In the previous edition of this statement, the Committee on Drugs placed nicotine (smoking) in Table  2 , "Drugs of Abuse-Contraindicated During Breastfeeding." The reasons for placing nicotine and, thus, smoking in Table 2 were documented decrease in milk production and weight gain in the infant of the smoking mother and exposure of the infant to environmental tobacco smoke as demonstrated by the presence of nicotine and its primary metabolite, cotinine, in human milk. 4 -12 There is controversy regarding the effects of nicotine on infant size at 1 year of age. 13, 14 There are hundreds of compounds in tobacco smoke; however, nicotine and its metabolite acotinine are most often used as markers of tobacco exposure. Nicotine is not necessarily the only component that might cause an increase in respiratory illnesses (including otitis media) in the nursing infant attributable to both transmammary secretion of compounds and environmental exposure. Nicotine is present in milk in concentrations between 1.5 and 3.0 times the simultaneous maternal plasma concentration, 15 and elimination half-life is similar-60 to 90 minutes in milk and plasma. 7 There is no evidence to document whether this amount of nicotine presents a health risk to the nursing infant.
The Committee on Drugs wishes to support the emphasis of the American Academy of Pediatrics on increasing breastfeeding in the United States. Pregnancy and lactation are ideal occasions for physicians to urge cessation of smoking. It is recognized that there are women who are unable to stop smoking cigarettes. One study reported that, among women who continue to smoke throughout breastfeeding, the incidence of acute respiratory illness is decreased among their infants, compared with infants of smoking mothers who are bottle fed. 16 It may be that breastfeeding and smoking is less detrimental to the child than bottle feeding and smoking. The Committee on Drugs awaits more data on this issue. The Committee on Drugs therefore has not placed nicotine (and thus smoking) in any of the Tables but hopes that the interest in breastfeeding by a smoking woman will serve as a point of discussion about smoking cessation between the pediatrician and the prospective lactating woman or nursing mother. Alternate (oral, transcutaneous) sources of nicotine to assist with smoking cessation, however, have not been studied sufficiently for the Committee on Drugs to make a recommendation for or against them in breastfeeding women. nervous system, it may not be possible to predict long-term neurodevelopmental effects.
SILICONE BREAST IMPLANTS AND BREASTFEEDING
Approximately 800 000 to 1 million women in the United States have received breast implants containing silicone (elemental silicon with chemical bonds to oxygen) in the implant envelope or in the envelope and the interior gel. Concern has been raised about the possible effects to the nursing infant if mothers with implants breastfeed. This concern was initially raised in reports that described esophageal dysfunction in 11 children whose mothers had implants. 17, 18 This finding has not been confirmed by other reports. Silicone chemistry is extremely complex; the polymer involved in the covering and the interior of the breast implant consists of a polymer of alternating silicon and oxygen atoms with methyl groups attached to the oxygen groups (methyl polydimethylsiloxane). 19 The length of the polymer determines whether it is a solid, gel, or liquid. There are only a few instances of the polymer being assayed in the milk of women with implants; the concentrations are not elevated over control samples. 20 There is no evidence at the present time that this polymer is directly toxic to human tissues; however, concern also exists that toxicity may be mediated through an immunologic mechanism. This has yet to be confirmed in humans. Except for the study cited above, there have been no other reports of clinical problems in infants of mothers with silicone breast implants. 21 It is unlikely that elemental silicon causes difficulty, because silicon is present in higher concentrations in cow milk and formula than in milk of humans with implants. 22 The anticolic compound simethicone is a silicone and has a structure very similar to the methyl polydimethylsiloxane in breast implants. Simethicone has been used for decades in this country and Europe without any evidence of toxicity to infants. The Committee on Drugs does not feel that the evidence currently justifies classifying silicone implants as a contraindication to breastfeeding.
DRUG THERAPY OF THE LACTATING WOMAN
The following should be considered before prescribing drugs to lactating women:
1. Is drug therapy really necessary? If drugs are required, consultation between the pediatrician and the mother's physician can be most useful in determining what options to choose. 2. The safest drug should be chosen, for example, acetaminophen rather than aspirin for analgesia. 3. If there is a possibility that a drug may present a risk to the infant, consideration should be given to measurement of blood concentrations in the nursing infant. 4. Drug exposure to the nursing infant may be minimized by having the mother take the medication just after she has breastfed the infant or just before the infant is due to have a lengthy sleep period.
Data have been obtained from a search of the medical literature. Because methodologies used to quantitate drugs in milk continue to improve, this information will require frequent updating. Drugs cited in Tables 1 through 7 are listed in alphabetical order by generic name; brand names are available from the current Physicians' Desk Reference, 23 USP DI 2001: Drug Information for the Health Care Professional, Volume I, 24 and USP Dictionary of USAN and International Drug Names. 25 The reference list is not inclusive of all articles published on the topic.
Physicians who encounter adverse effects in infants who have been receiving drug-contaminated human milk are urged to document these effects in a communication to the Food and Drug Administration (http://www.fda.gov/medwatch/index.html) and to the Committee on Drugs. This communication should include the generic and brand names of the drug, the maternal dose and mode of administration, the concentration of the drug in milk and maternal and infant blood in relation to the time of ingestion, the method used for laboratory identification, the age of the infant, and the adverse effects. Such reports may substantially increase the pediatric community's fund of knowledge regarding drug transfer into human milk and the potential or actual risk to the infant. Radioactivity in milk present 15 h to 3 d 41, 50-55 * Consult nuclear medicine physician before performing diagnostic study so that radionuclide that has the shortest excretion time in breast milk can be used. Before study, the mother should pump her breast and store enough milk in the freezer for feeding the infant; after study, the mother should pump her breast to maintain milk production but discard all milk pumped for the required time that radioactivity is present in milk. Milk samples can be screened by radiology departments for radioactivity before resumption of nursing. In vitro mutagen; may discontinue breastfeeding for 12-24 h to allow excretion of dose when single-dose therapy given to mother
113, 114
Tinidazole See metronidazole 115 * Psychotropic drugs, the compounds listed under anti-anxiety, antidepressant, and antipsychotic categories, are of special concern when given to nursing mothers for long periods. Although there are very few case reports of adverse effects in breastfeeding infants, these drugs do appear in human milk and, thus, could conceivably alter short-term and long-term central nervous system function. 56 See discussion in text of psychotropic drugs. † Drug is concentrated in human milk relative to simultaneous maternal plasma concentrations. * Drugs listed have been reported in the literature as having the effects listed or no effect. The word "none" means that no observable change was seen in the nursing infant while the mother was ingesting the compound. Dashes indicate no mention of clinical effect on the infant. It is emphasized that many of the literature citations concern single case reports or small series of infants. † Drug is concentrated in human milk. 
INTRODUCTION
L eading the list of Americans' concerns for children is drug abuse, according to a 1997 Harvard study. 1 The numbers of children, adolescents, and families affected by substance abuse have sharply increased since the early 1990s. 2 Unfortunately, the availability of and financing for substance abuse prevention, assessment, and treatment have not kept pace with the needs of young people. Access to substance abuse services has decreased during the past decade because of inadequate insurance coverage, managed care controls, and low reimbursement rates. Although there are no national estimates of unmet need for substance abuse services for children, the surgeon general estimated that as many as 75% to 80% of children who are in need of mental health treatment fail to receive it. 3 The consequences of failing to intervene early and not providing ageappropriate substance abuse and mental health treatment are substantial and long-term.
This policy statement includes a summary of the prevalence of substance abuse among children and adolescents along with a review of financing problems experienced by those who are insured through private health insurance, Medicaid, and the State Children's Health Insurance Program (SCHIP), and those who are uninsured. The statement concludes with specific recommendations for financing substance abuse prevention, assessment, and treatment for children and adolescents. By necessity, these recommendations incorporate mental health problems and interventions because of the high prevalence of comorbid psychiatric disorders among children with substance abuse problems.
PREVALENCE AND IMPACT OF SUBSTANCE ABUSE AMONG CHILDREN AND ADOLESCENTS
Substance abuse by young people has increased in the past decade, and it is occurring at younger ages. According to results from the Monitoring the Future Study conducted in 1999 at the University of Michigan Institute for Social Research, 33% of 12th graders and 9% of eighth graders reported being drunk 1 or more times during the last 30 days. 2 As many as 23% of high school seniors and 10% of eighth graders reported using marijuana in the last 30 days, up from 14% and 3%, respectively, in 1991. The percentage of adolescents who reported using hallucinogens, lysergic acid diethylamide (LSD), phencyclidine hydrochloride (PCP), cocaine and crack cocaine, heroin, amphetamines, methamphetamines, barbiturates, and tranquilizers also increased between 1991 and 1999. In addition, cigarette use among adolescents, which is a risk factor for use of marijuana and other illicit drugs, also markedly increased during this decade. In 1999, 35% of 12th graders reported smoking cigarettes during the last 30 days, up from 28% in 1991. Among eighth graders, the reported 30-day cigarette use rate increased from 14% to 18%.
Epidemiologic data revealed that 9% of adolescent females and 20% of adolescent males meet adult diagnostic criteria for an alcohol use disorder. 4 Among adolescents and young adults with a substance abuse disorder, 41% to 65% also have a mental health disorder. 3 The most common of these are depression, conduct disorder, and attention-deficit/hyperactivity disorder (ADHD) in combination with conduct disorder. ADHD and learning disorders in combination with depression and anxiety disorders also carry a high risk of substance abuse. If the significant number of drug-exposed infants and the 1 in 6 children exposed to substance abuse within their families are added to these estimates, the size of the population affected by substance abuse and, therefore, potentially needing assistance dramatically increases. 5 Obtaining accurate estimates of the prevalence of substance abuse among children and adolescents is very difficult. Most national studies survey only students, but many high-risk youth do not regularly attend school and, thus, are not included in these estimates. Other difficulties in obtaining reliable estimates are the results of coverage and reimbursement problems. Rather than using a substance abuse diagnosis, health care professionals may be using procedure codes for treating associated symptoms of substance abuse, such as fatigue, irritability, weight loss, headache, abdominal pain, or depression. The lack of use of substance abuse codes may also reflect health care professionals' attempt to avoid stigmatizing a child. Consequently, existing prevalence data likely underestimate the scope of the problem.
Data specific to adolescents are limited, but there is growing evidence that successful early intervention and treatment carries significant benefit for the individual and society. 6 The most appropriate assessment of costs and benefits of treatment are based on broader outcome measures rather than abstinence alone. Despite the fact that there is no single treatment approach that works for all patients, standard treatments have been shown to produce significant decreases in drug use and in drug-related problems of crime, family violence, unemployment, welfare dependence, underachievement, and other antisocial behaviors. 7
EXTENT OF FINANCING PROBLEMS FOR SUBSTANCE ABUSE SERVICES
Although most families whose children require substance abuse services experience financial difficulties related to high out-of-pocket expenses, those who are uninsured are at the greatest disadvantage. An estimated 14 million or 15.9% of children younger than 22 years had no health insurance coverage in 1999. 8 These families must rely exclusively on publicly funded services through their state's substance abuse and mental health agencies or must pay for care themselves. Often, uninsured youth receive uncompensated hospital and emergency care for acute symptoms only, which is seldom coordinated with primary care and behavioral health services. Unfortunately, publicly supported substance abuse and mental health services are underfunded and are typically available only for youth with serious emotional disturbances whose families meet a certain income threshold. Many young people, particularly those who are just beginning to abuse alcohol and other drugs, do not have serious emotional disturbances and, therefore, do not qualify for state-funded services. Moreover, children who are privately insured but without adequate substance abuse and mental health benefits are seldom eligible for statefunded services.
Most children under age 22 (65.4% or 57.7 million) are privately insured by plans purchased by their families individually or through their employers. 8 Often, these families rapidly exhaust their annual and even lifetime allotment of substance abuse benefits and must pay for needed services themselves or rely exclusively on self-help organizations, such as Alcoholics Anonymous and Narcotics Anonymous. Most private health insurance plans impose benefit limitations and cost-sharing requirements on substance abuse and mental health services that are greater than those imposed on general medical services. 9, 10 For example, coverage of outpatient substance abuse services, when available, is typically short in duration and is often capped at an inade-quate number of visits. Family therapy is often excluded. Inpatient substance abuse services are sometimes excluded altogether or covered only for acute detoxification purposes. Coverage of prevention, assessment, early intervention, relapse prevention, crisis intervention, partial hospitalization or day treatment, and residential care is seldom covered by private plans. Mental health benefits, however, are often provided somewhat more generously than are substance abuse benefits. 2, 11 In addition to benefit limitations, many private insurance plans require higher copayments or coinsurance in addition to separate deductibles for substance abuse benefits. 11 The Mental Health Parity Act of 1996 prohibits plans from imposing higher annual and lifetime out-of-pocket maximums for mental health services than for general medical services. 12 Although many states have passed mental health parity legislation, substance abuse parity is often not included. Thus, many of the gains that have been made in achieving parity only apply to mental health. This may perpetuate the pattern of physicians using procedure codes for treating associated symptoms of substance abuse rather than codes for a substance abuse diagnosis, which further distorts prevalence statistics. Also, the lack of specific data furthers the misconception that substance abuse is a consequence of mental illness rather than a primary disease, a comorbidity, or a significant precipitant of mental health problems.
Medicaid, the source of insurance for 16.4 million or 18.7% of all children younger than 22 years, has historically covered fewer adolescents than younger children. 8 Not until the enactment of SCHIP have many states taken the option to expand Medicaid to cover all adolescents from families with incomes at 100% of the federal poverty level. Unlike private coverage, Medicaid's benefits for children and adolescents are comprehensive and cover a continuum of inpatient and outpatient substance abuse and mental health services. Although Medicaid benefits are expansive, reimbursement rates have been very low and, as a result, serve as a disincentive to provide qualified pediatric and substance abuse services.
Regardless of the source of health insurance coverage, most substance abuse and mental health services are delivered by managed behavioral plans, distinct from general managed care plans and primary pediatric medical care. Although the literature shows that managed behavioral health plans have provided greater overall access to mental health services and a greater continuum of care, it also shows that as a result of tight utilization management, rates of ambulatory visits and hospitalizations have decreased. 3 Pediatricians and other referring health care providers report persistent problems in obtaining authorization for substance abuse treatment for children and adolescents. Often, utilization review criteria address the needs of adults, and children's conditions must be severe or associated with comorbidities to warrant extended counseling or hospital stays. For example, criteria such as chronicity, loss of work, and adult comorbidities-which are inappro-priate for young people-are often used to determine whether substance abuse treatment is medically necessary. Moreover, many behavioral health plans have closed panels of mental health professionals with limited pediatric substance abuse training or experience. Seldom does coordination between primary care and behavioral health care take place effectively. Problems have also been reported in sharing medical information between behavioral health plans and primary care providers.
Compounding these difficulties is the overall shortage of ambulatory and inpatient substance abuse and mental health services for children and adolescents. Many inpatient facilities have closed during recent years. These shortages have resulted from many factors, including historically low rates of reimbursement provided to substance abuse and mental health professionals. To serve this population effectively is very labor intensive, and insurance dollars and public funds consistently fail to provide adequate reimbursement. Also contributing to payment and service gaps is the fact few insurers recognize the new Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: Primary Care Version, which was developed jointly by the pediatric and mental health communities to encourage earlier identification and primary behavioral interventions. 13 In addition, pediatricians are seldom able to receive reimbursement for providing counseling and education services to children at high risk of developing substance abuse problems.
Serious problems exist in the availability and organization of behavioral health services for the treatment of substance abuse problems among youth. Although there are substantial problems with low payment and persistent obstacles in gaining access to needed interventions, pediatricians are in a unique role to identify and intervene with children and adolescents who have or are at risk of substance abuse problems. 14 In addition, a cadre of physicians needs to be trained in the field of pediatric addiction medicine. However, the recruitment and retention of pediatricians and other health care providers in the field of addiction medicine has been very difficult, which seriously compromises the provision of highquality substance abuse care. 14 
FINANCING RECOMMENDATIONS
Many changes need to be made to the financing and delivery of substance abuse care to improve the availability of services for all children and adolescents. Change in this area, however, is not likely to occur without the participation of a coalition of national and state legislators, public purchasers, employers, health professionals, families, and health services researchers. The American Academy of Pediatrics, together with other participating behavioral health organizations and consumer groups, released a consensus statement on insurance coverage for mental health and substance abuse services for children and adolescents, which highlights the deterioration of mental health and substance abuse services and recommends access, coordination, and monitoring strategies for achieving service improvements. 15 That article and this policy statement on financing should serve as blueprints for Congress, federal and state policy-makers, and employers.
The American Academy of Pediatrics recommends that Congress authorize the Substance Abuse and Mental Health Services Administration to conduct a comprehensive national study of the supply, distribution, financing, and quality of substance abuse prevention, assessment, and treatment services for children and adolescents.
Additional recommendations address the needs of all children, regardless of insurance status. In addition, there are specific recommendations that apply to those with private insurance, those with Medicaid or SCHIP coverage, and those who are uninsured.
For All Children and Adolescents, Regardless of Insurance Status
1. Ensure that substance abuse and mental health benefits are sufficient in amount, duration, and scope to reasonably achieve their purpose. 2. Allow pediatricians and safety net providers trained or experienced in substance abuse prevention, assessment, evaluation, and management services to be included in panels of professionals that provide these services. 3. Create an integrated system of referral and treatment for substance abuse that is consistent with the referral and treatment process of other chronic diseases. 4. Simplify and coordinate processes for families attempting to access substance abuse and mental health services for their children across public and private insurers plans, and public programs. 5. Improve preauthorization and utilization review criteria to be consistent with national standards on the treatment of substance abuse among youth developed by the American Academy of Pediatrics, 16 the Substance Abuse and Mental Health Services Administration, 17 the National Institute on Alcohol Abuse and Alcoholism, 18 and the American Society of Addiction Medicine. 19 6. Provide reasonable compensation and allow reimbursement of counseling, coordination, and consultation procedure codes to enable pediatricians and other primary care providers to provide primary substance abuse and mental health services. 7. Adjust capitation rates to take into account substance abuse service needs and recommended clinical guidelines for length of care for children and adolescents rather than relying on historic utilization rates to establish capitation amounts. 19 
Encourage payers to reimburse for individual
and group counseling and risk factor reduction interventions for children at risk of substance abuse problems. 9. Establish financing mechanism for smoking cessation programs for children. 10. Create financial incentives for comanagement of substance abuse treatment between primary care and behavioral health care (eg, transferring some behavioral health dollars into primary care).
11. Create mechanisms for sharing risk among public and private payors to allow for coverage of a comprehensive set of interventions to better manage children with complex cases. 12. Establish clear delineation of responsibilities with regard to children involved with multiple state agencies and required court-ordered treatment. 13. Ensure that health plans and health care providers adopt medical record and billing procedures to protect the confidentiality of children and adolescents.
For Privately Insured Children and Adolescents 1. Extend benefits to include a broader array of substance abuse prevention, assessment, and treatment services. 2. Establish parity between medical services and substance abuse and mental health services so that coverage of the management of substance abuse and mental health disorders is the same as coverage of other chronic conditions. 3. Reduce limitations on substance abuse and mental health services and allow for substitution of mental health and substance abuse benefits and use of alternative sites of care, including schools and homes. 4. Eliminate exclusions for specific diagnostic categories, chronic disorders, and preexisting conditions. 5. Reduce cost-sharing requirements for substance abuse services to encourage their use.
For Medicaid and SCHIP Insured Children and Adolescents
1. Target outreach efforts to ensure that Medicaidand SCHIP-eligible adolescents are covered. 2. Ensure that a continuum of substance abuse and mental health services for children and adolescents are specified in state Medicaid plans and contracts, using a variety of benefit categories, including Early and Periodic Screening, Diagnosis, and Treatment expanded services. 3. In non-Medicaid SCHIP programs, offer supplemental or wraparound benefits to allow expanded behavioral health coverage for those who meet certain risk criteria.
For Uninsured Children and Adolescents

